Eurofins Launches Reagents for Automated Extraction of Genomic SARS-CoV-2 RNA from Clinical Swab Samples
By HospiMedica International staff writers Posted on 10 Aug 2020 |
GSD NovaPrime SARS-CoV-2 (COVID 19) - (Photo courtesy of Eurofins Technologies)
Eurofins Technologies (Luxembourg) has launched reagents for automated isolation of high-quality SARS-CoV-2 RNA (ribonucleic acid) from viral particles of human respiratory specimens.
As COVID-19 continues to accelerate worldwide, diagnostic laboratories face an unprecedented demand for testing capacity. Eurofins' launch of the GSD NovaPrime RNA Extraction kits aims to help laboratories to meet this demand with an easy and highly efficient extraction method that works with a large range of existing automation equipment.
The GSD NovaPrime RNA Extraction AE1 kit is intended for the automated extraction of genomic SARS-CoV-2 RNA from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab) specimen types, specifically validated for the use with the KingFisher Flex System automation platform. The GSD NovaPrime RNA Extraction AE2 kit is intended for automated extraction of genomic SARS-CoV-2 RNA from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab) specimen types, specifically validated for the use with the MGI MGISP-960 automation platform.
The reagents’ magnetic bead-based, automated method extracts and isolates virus particles and their respective RNA on many open platforms for subsequent real-time RT-PCR (reverse transcription polymerase chain reaction) analysis using approved IVD kits. Both the kits are ideal for use with the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR clinical IVD assay for virus detection. The kits have to be validated as required by local legislation for their intended use by authorized clinical testing laboratories. Eurofins also plans to release a CE-IVD marked version of the kit at a later stage.
Related Links
Eurofins Technologies
As COVID-19 continues to accelerate worldwide, diagnostic laboratories face an unprecedented demand for testing capacity. Eurofins' launch of the GSD NovaPrime RNA Extraction kits aims to help laboratories to meet this demand with an easy and highly efficient extraction method that works with a large range of existing automation equipment.
The GSD NovaPrime RNA Extraction AE1 kit is intended for the automated extraction of genomic SARS-CoV-2 RNA from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab) specimen types, specifically validated for the use with the KingFisher Flex System automation platform. The GSD NovaPrime RNA Extraction AE2 kit is intended for automated extraction of genomic SARS-CoV-2 RNA from human respiratory (nasal wash/swab, nasopharyngeal wash/swab, oropharyngeal swab) specimen types, specifically validated for the use with the MGI MGISP-960 automation platform.
The reagents’ magnetic bead-based, automated method extracts and isolates virus particles and their respective RNA on many open platforms for subsequent real-time RT-PCR (reverse transcription polymerase chain reaction) analysis using approved IVD kits. Both the kits are ideal for use with the GSD NovaPrime SARS-CoV-2 (COVID-19) RT-PCR clinical IVD assay for virus detection. The kits have to be validated as required by local legislation for their intended use by authorized clinical testing laboratories. Eurofins also plans to release a CE-IVD marked version of the kit at a later stage.
Related Links
Eurofins Technologies
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans